Nutrigenetics, Metabolic Syndrome Risk and Personalized Nutrition

Curr Vasc Pharmacol. 2013 Nov;11(6):946-53. doi: 10.2174/157016111106140128120911.

Abstract

The metabolic syndrome (MetS) is a constellation of metabolic risk factors reflecting overnutrition and sedentary lifestyle and its increasing prevalence is reaching epidemic proportions. The importance of MetS lies in its close association with the risk of cardiometabolic disease. In this scenario, the principal goals of pharmacological therapy for these patients are to achieve and maintain an optimal cardiometabolic control, including lipids, blood glucose and blood pressure; in order to prevent and treat potential complications. Moreover nutrition has commonly been accepted as a cornerstone of treatment for MetS, with the expectation that an appropriate intake of energy and nutrients will improve its control. However the question arises as to whether dietary therapy may require a more personalised approach. In this regard improvements in genetic analysis have enhanced our understanding of the role of genetics in this dietrelated condition. In this review we will present recent data highlighting the importance of gene-nutrient interactions in the context of MetS risk.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Blood Glucose / metabolism
  • Diet / adverse effects
  • Diet / methods
  • Diet / trends*
  • Fatty Acids / administration & dosage
  • Fatty Acids / adverse effects
  • Humans
  • Metabolic Syndrome / diet therapy*
  • Metabolic Syndrome / genetics*
  • Nutrigenomics / methods*
  • Nutrigenomics / trends
  • Nutritional Status / physiology*
  • Precision Medicine / methods
  • Precision Medicine / trends*
  • Risk Factors

Substances

  • Blood Glucose
  • Fatty Acids